Biological
Cohort 3
Cohort 3 is a biological therapy with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_1
4
80%
Ph phase_2
1
20%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (80.0%)
Phase 21 (20.0%)
Trials by Status
completed480%
active_not_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruitingphase_1
CD22 Redirected Autologous T Cells for ALL
NCT02650414
completedphase_1
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
NCT00439179
completedphase_1
Phase I Study of Safety and Immunogenicity of ADU-623
NCT01967758
completedphase_1
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT01400555
completedphase_2
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
NCT02604485
Clinical Trials (5)
Showing 5 of 5 trials
NCT02650414Phase 1
CD22 Redirected Autologous T Cells for ALL
NCT00439179Phase 1
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
NCT01967758Phase 1
Phase I Study of Safety and Immunogenicity of ADU-623
NCT01400555Phase 1
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT02604485Phase 2
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5